WPD103 is a radiopharmaceutical based on the expression of tumor specific receptors, such as IL-13RA2 and EphA2, which are not detected in normal cells, which express mainly IL-13RA1 and Eph-RA1 proteins.

The breakthrough of WPD Pharmaceuticals’ solution is expected to be a new diagnostic tool and targeted therapy against IL-13RA2 and EphA2 receptors by genetically modified IL-13 and Ephrin 1 cytokines, conjugated to radionuclides. Recombinant cytokines preferentially bound to tumor-specific receptors will allow for highly specific targeting of cancer cells and their further elimination due to radiation induced cytotoxic effects. The Project's result should allow patients access to an innovative molecular diagnostic tool and, later, targeted therapies as an alternative to conventional treatment. The solution falls within the scope of theranostics, a novel approach combining diagnostics with cancer therapy.